Although EGFR is upregulated in gastric cancer, EGFR-targeted therapies have shown marginal clinical effect in gastric cancer patients without any predictive biomarkers (Lordick et al, 2013; Waddell et al, 2013). The gene discussed is EGFR; the disease is gastric cancer.